Royal Bank Of Canada Cuts Pharvaris (NASDAQ:PHVS) Price Target to $51.00

Pharvaris (NASDAQ:PHVS) had its price objective lowered by Royal Bank Of Canada from $52.00 to $51.00 in a report published on Monday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Several other equities analysts have also recently commented on PHVS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a report on Tuesday, March 3rd. Finally, Wall Street Zen cut shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Sunday. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $42.80.

Pharvaris Stock Performance

Shares of PHVS stock opened at $27.56 on Monday. Pharvaris has a one year low of $11.51 and a one year high of $29.85. The company’s 50-day simple moving average is $27.07 and its 200-day simple moving average is $25.50. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -8.18 and a beta of -2.58.

Hedge Funds Weigh In On Pharvaris

Large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new position in Pharvaris in the fourth quarter worth about $35,000. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris in the third quarter worth about $75,000. Barclays PLC acquired a new stake in shares of Pharvaris in the fourth quarter valued at approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Pharvaris in the fourth quarter valued at approximately $86,000.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $60 price target while materially raising several multi‑year earnings forecasts (notably FY2028–FY2030 and FY2029 EPS to $1.64 from $1.27), signaling stronger long‑term profitability expectations for Pharvaris. HC Wainwright analyst note
• Positive Sentiment: Wedbush raised its price target to $42 and kept an “Outperform” rating, which supports upside sentiment from another sell‑side firm and may attract momentum buyers. Benzinga note
• Neutral Sentiment: Brokerage coverage remains broadly favorable — reports show an average rating around “Moderate Buy,” reflecting mixed but generally constructive analyst views that could limit downside. Consensus rating article
• Neutral Sentiment: Analyst commentary and a recent feature examine the shift in Pharvaris’ investment narrative after Phase 3 activity and 2025 losses — useful context for investors but not a direct catalyst on its own. Yahoo Finance piece
• Negative Sentiment: HC Wainwright made small near‑term downward tweaks to Q1 and Q2 2026 EPS (e.g., Q1 to ($0.83) from ($0.80), Q2 to ($0.89) from ($0.87)), which highlight weaker near-term profitability versus prior expectations and can pressure short‑term sentiment. HC Wainwright estimates
• Negative Sentiment: Royal Bank of Canada published a pessimistic forecast for PHVS, adding downside analyst noise and potentially increasing selling pressure from cautious investors. RBC outlook

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.